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Objectives. The purpose of the study was to assess the effects of
maternal HIV-1 (human immunodeficiency virus) infection and
vertically transmitted HIV-1 infection on the prevalence of con-
genital cardiovascular malformations in children.
Background. In the United States, an estimated 7000 children
are born to HIV-infected women annually. Previous limited re-
ports have suggested an increase in the prevalence of congenital
cardiovascular malformations in vertically transmitted HIV-
infected children.
Methods. In a prospective longitudinal multicenter study, di-
agnostic echocardiograms were performed at 4–6-month intervals
on two cohorts of children exposed to maternal HIV-1 infection: 1)
a Neonatal Cohort of 90 HIV-infected, 449 HIV-uninfected and 19
HIV-indeterminate children; and 2) an Older HIV-Infected Co-
hort of 201 children with vertically transmitted HIV-1 infection
recruited after 28 days of age.
Results. In the Neonatal Cohort, 36 lesions were seen in 36
patients, yielding an overall congenital cardiovascular malforma-
tion prevalence of 6.5% (36/558), with a 8.9% (8/90) prevalence in
HIV-infected children and a 5.6% (25/449) prevalence in HIV-
uninfected children. Two children (2/558, 0.4%) had cyanotic
lesions. In the Older HIV-Infected Cohort, there was a congenital
cardiovascular malformation prevalence of 7.5% (15/201). The
distribution of lesions did not differ significantly between the
groups.
Conclusions. There was no statistically significant difference in
congenital cardiovascular malformation prevalence in HIV-
infected versus HIV-uninfected children born to HIV-infected
women. With the use of early screening echocardiography, rates of
congenital cardiovascular malformations in both the HIV-infected
and HIV-uninfected children were five- to ten-fold higher than
rates reported in population-based epidemiologic studies but not
higher than in normal populations similarly screened. Potentially
important subclinical congenital cardiovascular malformations
were detected.
(J Am Coll Cardiol 1998;32:1749–55)
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There has been a rapid rise in the number of women of
child-bearing age infected with the human immunodeficiency
virus type 1 (HIV-1) (1). In the United States, an estimated
7000 children are born to HIV-infected women annually, and
mother-to-child transmission accounts for 95% of the reported
AIDS cases in children under 4 years of age (2).
The association of vertically transmitted HIV-1 infection
with left ventricular dysfunction and dilated cardiomyopathy
has been well established in infants and children (3,4). How-
ever, the effect of maternal HIV-1 infection on the prevalence
of congenital cardiovascular malformations is unknown. An
abstract published in 1988 by Vogel and colleagues (5) re-
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ported a congenital cardiovascular malformation prevalence of
2.8% (5/175) in an uncontrolled study population of HIV-
infected children. Three of the five patients required cardiac
catheterization and surgery. That same year, the Italian Mul-
ticentre Study (6) reported a four-fold increase in the preva-
lence of congenital cardiovascular malformations in 165 HIV-
infected children when compared to historical control data
(2.4% vs. 0.6%).
The Prospective P2C2 HIV Multicenter Study (P2C2 HIV
Study) was initiated to provide a systematic surveillance of
Pediatric Pulmonary and Cardiovascular Complications (P2C2)
commonly seen in children exposed to maternal HIV-1 infec-
tion. The purpose of the present report was to examine the
effects of maternal HIV-1 infection and vertically transmitted
HIV-1 infection on the prevalence of congenital cardiovascular
malformations in children born to HIV-infected women.
Methods
From May 1990 to January 1994, HIV-infected women and
their children were recruited into the P2C2 HIV Study at five
clinical centers located in four major metropolitan areas.
Studies evaluating the long-term effects of HIV-1 morbidity
were performed in accordance with a protocol approved by the
Institutional Review Board at each of the clinical centers.
Informed consent to participate in the study was obtained from
the appropriate family member of all patients. A detailed
description of recruitment and retainment strategies for the
P2C2 HIV Study has been provided elsewhere (7).
The P2C2 HIV Study recruited two study cohorts. The
Neonatal Cohort (also referred to as group II in other P2C2
publications) was composed of infants born to HIV-infected
women enrolled during gestation or by 28 days after birth. A
randomly selected group of HIV-uninfected children from this
cohort was followed throughout the study as a comparison
group (Neonatal Cohort/Comparison Group) for the HIV-
infected children (Neonatal Cohort/HIV-Infected Group).
The Older HIV-Infected Cohort (also referred to as group I in
other P2C2 publications) was composed of children enrolled at
more than 28 days of age with documented vertically transmit-
ted HIV-1 infection. This group was selected to provide
information on the later stages of HIV-1 infection in child-
hood. Children who were classified as P-2, subclass E (cancer),
at enrollment according to the 1987 Revised Centers for
Disease Control Classification System were excluded from the
study (8).
Maternal HIV-1 status was determined by antibody testing
with an enzyme-linked immunosorbent assay (ELISA) and
confirmed by Western blot. The HIV-1 status of the infant was
determined by viral culture upon recruitment, at 3 months, and
at 6 months of age. An HIV-negative status was confirmed by
antibody testing at a minimum of 15 months of age. Children
who were lost to follow-up or died prior to confirmation of
HIV-1 status were classified as HIV-indeterminate. Measure-
ments of maternal CD4 lymphocyte number and percent were
obtained at delivery in laboratories that used AIDS Clinical
Trials Group quality assurance protocols.
Throughout the study, a screening physical examination was
routinely performed by a P2C2 nurse prior to each echocardio-
gram. The presence or absence of a murmur was recorded.
From March 1994 to January 1997, the P2C2 HIV Study
protocol included physical examination findings of a pediatric
cardiologist on all patients suspected of having a congenital
cardiovascular malformation or congestive heart failure.
Diagnostic anatomical echocardiograms and left ventricular
function and contractility analyses were performed according
to the P2C2 protocol at 10 designated noninvasive laboratories
affiliated with the five participating clinical centers. Echocar-
diograms were performed upon enrollment into the study and
at 4-month intervals prior to determination of HIV-infection
status. Echocardiograms continued at 4-month intervals
throughout the study for the HIV-infected children. Chloral
hydrate was used for sedation in children under 3 years of age
when necessary. Children who were determined to be HIV-
negative subsequently obtained echocardiograms at 6-month
intervals without sedation.
Echocardiograms were recorded on VHS or SVHS video-
tapes for subsequent review. The studies were supervised and
reviewed by staff pediatric cardiologists at the clinical centers.
The finding of a congenital cardiovascular malformation and
its status on later studies were reported to a central data
coordinating center. The persistence of a congenital cardiovas-
cular malformation at 1 year of age was established by notation
of the malformation on an echocardiogram at or beyond 1 year
of age.
Several quality assessments were performed to ensure
uniformity of quality and diagnostic capability of the echocar-
diograms. During the initial stages of the study, a random
sample of 44 echocardiograms with normal and abnormal
findings was collected for a blind review by a P2C2 cardiologist
at another clinical center. Thereafter, only studies positive for
a congenital cardiovascular malformation were routinely re-
viewed by a second P2C2 cardiologist. After completion of the
data collection phase, a subsequent blind review of 25 Neona-
tal Cohort studies with abnormal findings was performed by a
single P2C2 cardiologist (S.E.D.) to further refine the study
diagnostic criteria for congenital cardiovascular malforma-
tions. There was agreement on the primary diagnosis in 21 of
the 25 cases reviewed (84%). Based on this blind review and
other quality assurance measures, the diagnostic criteria for
congenital cardiovascular malformations were then modified
to exclude transient right-sided flow lesions. There was agree-
ment between the initial reading and blind review in all of the
cases ultimately included in the primary rate calculations,
excluding the diagnosis of patent foramen ovale.
Abbreviations and Acronyms
HIV 5 human immunodeficiency virus
P2C2 5 pediatric pulmonary and cardiac complications
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Diagnostic criteria and excluded diagnoses. Standard di-
agnostic definitions were utilized for congenital cardiovascular
malformations. In all cases, the diagnosis of a congenital
cardiovascular malformation required verification of the lesion
upon subsequent review by a P2C2 cardiologist at the clinical
center in which the study was performed. Structural lesions
believed to be possibly normal stages of cardiovascular devel-
opment were excluded from the primary calculations of con-
genital cardiovascular malformation prevalence: an atrial sep-
tal defect at less than 2 months of age, a patent ductus
arteriosus at less than 2 months of age, and a patent foramen
ovale at any age. After quality assurance review, transient
right-sided flow abnormalities without a hemodynamically
significant gradient (defined as a gradient of 10 mm Hg or
greater) were also excluded. Only right-sided flow lesions that
were identified on two or more echocardiograms, with at least
one notation beyond 1 year of life, were included in the
analyses.
Statistical analysis. The prevalence of congenital cardio-
vascular malformations was estimated as a proportion. Confi-
dence intervals (CI 95%) were calculated for prevalence rates
within each study cohort and by HIV-1 status within the
Neonatal Cohort. The prevalence rates were compared be-
tween groups using a chi-square test or a Fisher exact test.
Maternal CD4 lymphocyte count and percent were compared
by the HIV-1 status of the child and separately by the
congenital cardiovascular malformation status of the child
using the Wilcoxon rank-sum test. Logistic regression was used
to examine the joint association of HIV-1 status and congenital
cardiovascular malformation status on the detection of a
cardiac murmur.
Results
Patients. A total of 611 fetuses or live-born infants were
enrolled in the Neonatal Cohort including 11 fetuses and 600
live births. Of the 600 live-born children, 558 had one or more
echocardiograms (n 5 90 HIV-positive, n 5 449 HIV-negative,
and n 5 19 HIV-indeterminate) and formed the study popu-
lation. Forty-two children had no echocardiograms, including 8
children who died (n 5 2 HIV-positive and n 5 6 HIV-
indeterminate), 28 lost to follow-up (n 5 1 HIV-positive, n 5
8 HIV-negative, and n 5 19 HIV-indeterminate), and 6
children randomized off study without having an echocardiogram
(all HIV-negative). Two hundred sixteen HIV-uninfected chil-
dren from 204 mothers were randomly selected to be followed
as a comparison group (Neonatal Cohort/Comparison Group)
from the HIV-negative infants.
Among the 558 infants from the Neonatal Cohort with one
or more echocardiograms, 291 (52.2%) were male. Most of the
infants were either black (n 5 282, 50.5%) or Hispanic (n 5
175, 31.4%). The demographic profiles of the HIV-infected
and HIV-uninfected groups were similar. Among the 85 HIV-
infected and 412 HIV-uninfected children who had two or
more echocardiograms, the median number of echocardio-
grams completed in the first year of life was four and three,
respectively.
There were a total of 205 children enrolled in the Older
HIV-Infected Cohort. Among the 201 children with one or
more echocardiograms, the median age at the time of enroll-
ment was 23.0 months, with a range of 1.7 to 166.0 months. A
majority of the 201 children were female (n 5 109, 54.2%), and
most were either black (n 5 88, 43.8%) or Hispanic (n 5 79,
39.3%). The gender and race characteristics of the Older
HIV-Infected Cohort were not significantly different from the
Neonatal Cohort.
Neonatal cohort/HIV-infected and comparison groups.
The overall prevalence of congenital cardiovascular malforma-
tions was 6.5% (36/558) among children in the Neonatal
Cohort with a median age at cardiovascular diagnosis of 102
days (Table 1). There was no statistically significant difference
in the rates of congenital cardiovascular malformation preva-
lence obtained at the five clinical centers: Baylor (5.1%),
Boston (9.6%), Mt. Sinai (8.3%), Presbyterian (3.7%), and
UCLA (8.0%). There was no statistically significant difference
detected in the congenital cardiovascular malformation prev-
alence among HIV-infected (8.9%) and HIV-uninfected
(5.6%) children. The observed difference in congenital cardio-
vascular malformation prevalence rates between HIV-infected
and HIV-uninfected children was 3.3% with a 95% CI of
23.0% to 9.5%. There was no statistically significant difference
in the median age at first detection between the HIV-infected
group and the HIV-uninfected group (29 vs. 107 days, p 5
0.42).
Thirty-six congenital cardiovascular malformations were
diagnosed in 36 children within the Neonatal Cohort (Table 2).
Table 1. Prevalence of Congenital Cardiovascular Malformations (CCM) in Infants (Neonatal Cohort)
of HIV-Infected Mothers
Group No. Infants No. CCM % 95% CI
Median Age CCM
Identified (days)
HIV-infected 90 8 8.9 3.9%, 16.8% 29
HIV-uninfected 449 25 5.6 3.6%, 8.1% 107
HIV-indeterminate 19 3 15.8 3.4%, 39.6% 64
HIV-infected and
HIV-uninfected
539 33 6.1 4.3%, 8.5% 105
All infants 558 36 6.5 4.6%, 8.8% 102
Patent ductus arteriosus (PDA) and atrial septal defect (ASD) in infants ,2 months of age, right-sided lesions that
did not persist, and all patent foramen ovale (PFOs) were excluded.
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The distribution of congenital cardiovascular malformations in
HIV-infected versus HIV-uninfected children was similar, and
rare or uncommon malformations were not identified at
unexpectedly high rates (Tables 2 and 3). Only one case of
patent ductus arteriosus was associated with prematurity. A
number of normally subclinical congenital cardiovascular mal-
formations, such as a bicuspid aortic valve without stenosis or
regurgitation, a persistent left superior vena cava, and a small
coronary arteriovenous fistula, were identified on the screening
echocardiograms. These lesions comprised 6 out of the 36
congenital cardiovascular malformations detected (16.7%) in
the Neonatal Cohort.
A heart murmur was noted on 24.2% (129/534) of children
with a known HIV-1 status within the Neonatal Cohort. A
murmur was more common among HIV-infected infants
(35.6% vs. 21.9%, p 5 0.008) and tended to be more frequent
among infants with a congenital cardiovascular malformation
(39.4% vs. 23.2%, p 5 0.05). Among the group of 36 Neonatal
Cohort children with a congenital cardiovascular malforma-
tion, 14 (38.9%) had a murmur detected.
The two children with a cyanotic congenital cardiovascular
malformation (2/558, 0.4%) underwent successful surgical
repair. A patient with obstructed total anomalous pulmonary
venous return was repaired at 2 days of age, and a patient with
a ventricular septal defect and pulmonary stenosis was cor-
rected at 3 years of age. No other child studied required
cardiac catheterization or surgical intervention for a congenital
cardiovascular malformation. Two children with a secundum
atrial septal defect had evidence of right ventricular hypertro-
phy on electrocardiogram. Neither had evidence of persistent
right ventricular volume overload on echocardiogram (as
defined by diastolic septal flattening). In addition, no child with
an isolated ventricular septal defect or patent ductus arteriosus
had evidence of a hemodynamically significant left to right
shunt on echocardiogram (as defined by left ventricular dila-
tation).
Persistence of a congenital cardiovascular malformation
was documented on a follow-up echocardiogram in 56%
(19/34) of children with a known HIV-1 status at 1 year of age
(Table 3). There was a trend toward congenital cardiovascular
malformation persistence in HIV-infected (6/85, 7.1%) versus
HIV-uninfected children (13/412, 3.2%; p 5 0.11).
Congenital cardiovascular malformation status of the child
did not correlate with severity of maternal HIV-1 infection as
measured by CD4 cell count. There was no significant differ-
ence in median values of maternal CD4 number and percent
between the children with a congenital cardiovascular malfor-
mation (n 5 29, 484 cells/mm3 and 29%) versus the control
group children (n 5 454, 423 cells/mm3 and 27%).
Table 2. Summary of All Congenital Cardiovascular Malformations
(CCM) Among 558 Infants From the Neonatal Cohort
CCM Frequency %
Cyanotic Lesions
Total anomalous pulmonary venous return 1 0.2




Secundum atrial septal defect 7 1.3
Ventricular septal defect 11 2.0
Patent ductus arteriosus 9 1.6
Right-sided Lesions
Supravalvar pulmonary stenosis 1 0.2
Left-sided Lesions
Bicuspid aortic valve 2 0.4
Miscellaneous Lesions
Persistent left superior vena cava 1 0.2
Coronary arteriovenous fistula 3 0.5
Total 36 6.5
Table 3. Prevalence of Congenital Cardiovascular Malformations (CCM) and Lesion Status at One Year of Age Among the Neonatal Cohort
CCM
HIV-Infected
(n 5 90) Follow-up HIV-Infected (n 5 85)
HIV-Uninfected
(n 5 449) Follow-up HIV-Uninfected (n 5 412)
No. Infants % Persisted Resolved Unknown No. Infants % Persisted Resolved Unknown
Cyanotic lesion 1 1.1 1 1 0.2 1
Secundum atrial septal
defect
2 2.2 1 1 5 1.1 3 2
Ventricular septal defect 3 3.3 2 1 8 1.8 1 6 1
Patent ductus
arteriosus*
1 1.1 1 5 1.1 3 1 1
Supravalvar pulmonary
stenosis
1 1.1 1 0
Bicuspid aortic valve 0 2 0.5 2
Persistent left superior
vena cava
0 1 0.2 1
Coronary arteriovenous
fistula
0 3 0.7 2 1
No. infants and percent 8 8.9 6/85 2/85 0/85 25 5.6 13/412 10/412 2/412
7.1% 2.4% 0.0% 3.2% 2.4% 0.5%
*Each of the three HIV indeterminate infants with a CCM had a patent ductus arteriosus.
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Older HIV-infected cohort. The prevalence of congenital
cardiovascular malformations in the Older HIV-Infected Co-
hort was 7.5% (95% CI 4.2%, 12.0%). Sixteen lesions were
diagnosed in 15 children (Table 4). Median age at the time of
diagnosis was 16.8 months. The congenital cardiovascular
malformation prevalence was similar in the Older HIV-
Infected Cohort and the Neonatal Cohort/HIV-Infected
Group (7.5% and 8.9%, respectively). There was also no
statistically significant difference in the prevalence of congen-
ital cardiovascular malformations between children in the
Older HIV-Infected Cohort and the Neonatal Cohort as a
whole.
Patent foramen ovale. A patent foramen ovale was seen
after 1 year of age in 13 children within the Neonatal Cohort
(13/534, 2.4%). Two of the 13 children were HIV-infected, and
11 were HIV-uninfected. A patent foramen ovale was seen
after 1 year of age in 10 children within the Older HIV-
Infected Cohort (10/201, 5.0%). The inclusion of patent fora-
men ovale in the calculations of congenital cardiovascular
malformation prevalence did not result in any statistically
significant increases (Table 5). Three infants in the Neonatal
Cohort had a patent foramen ovale in addition to another
congenital cardiovascular malformation, resulting in 49 lesions
among 46 infants.
Discussion
Effect of maternal HIV-1 infection. Development within
the uterine environment of an HIV-infected woman may have
untoward effects on fetal cardiac development regardless of
the status of HIV-1 transmission to the fetus. As previously
published, self-reported rates of maternal illicit drug use,
smoking and alcohol consumption were high in our study
population, but the rates were similar in mothers of HIV-
infected and mothers of HIV-uninfected children (9).
The congenital cardiovascular malformation prevalence in
both the Neonatal Cohort and the Older HIV-Infected Cohort
was five- to ten-fold higher than the 0.4% to 1.4% prevalence
reported in population-based epidemiologic studies (10–14).
The children in either P2C2 study cohort underwent multiple
echocardiographic examinations that yielded a high rate of
structural lesions. Of the patients with a congenital cardiovas-
cular malformation, ,40% had a murmur detected. Many of
these lesions would not have been reported in population-
based studies in which cases were primarily identified after
referral for evaluation of a murmur or for clinical evidence of
congestive heart failure.
Several reports describe the prevalence of congenital car-
diovascular malformations based on screening echocardiogra-
phy at an early age. Ooshima and colleagues (15) examined
502 consecutive neonates and discovered 19 cases (3.8%) of
congenital cardiovascular malformations: 10 ventricular septal
defect (2.0%), 4 atrial septal defect (0.8%), 2 pulmonary
stenosis (0.4%), and 1 each of aortic stenosis, endocardial
cushion defect and tricuspid regurgitation (0.2%). During the
first 12 months, 8 of 10 ventricular septal defects and all 4 atrial
septal defects closed spontaneously, giving a 1.0% prevalence
of congenital cardiovascular malformations at 1 year. Hirashi
and colleagues (16) reported a 2.0% prevalence of muscular
ventricular septal defect in a cohort of 1028 newborns with a
76% spontaneous closure rate by 1 year of age. A murmur was
present in 42% of the patients at the time of initial echocar-
diographic examination. Roguin and colleagues (17) reported
a 5.3% prevalence of muscular ventricular septal defect in 1053
newborns with an 89% spontaneous closure rate by 10 months
of age. Only 11% of the patients had clinical evidence of a
ventricular septal defect at the time of echocardiographic
diagnosis.
In our Neonatal Cohort, children of HIV-infected women,
9 of the 12 ventricular septal defects were muscular in location
(including a patient with a ventricular septal defect and
pulmonary stenosis), yielding a 1.6% prevalence of muscular
ventricular septal defect. There was a 1.3% prevalence of
secundum atrial septal defect. Both of these rates are compa-
rable to the available normal population data as determined by
early screening echocardiography.
Because of the high rate of early spontaneous resolution of
certain lesions, the timing of echocardiographic screening may
affect the number of congenital cardiovascular malformations
detected. Spontaneous closure of an atrial septal defect (18,19)
or a ventricular septal defect (15–17) within the first several
Table 4. Summary of All Congenital Cardiovascular Malformations
(CCM) Among 201 Infants From the Older HIV-Infected Cohort
Abnormality Frequency %
Shunt Lesions
Secundum atrial septal defect 4 2.0
Ventricular septal defect 1 0.5
Patent ductus arteriosus 2 1.0
Right-sided Lesions
Tricuspid valve prolapse 1 0.5
Valvar pulmonary stenosis 1 0.5
Left-sided Lesions
Mitral valve prolapse 5 2.5
Subaortic stenosis 1 0.5
Miscellaneous Lesions
Single coronary artery system 1 0.5
Total 15* 7.5%*
*Sixteen lesions in 15 infants and children.
Table 5. Prevalence of Congenital Cardiovascular Malformations
(CCM) Among the Neonatal Cohort Including Patent Foramen
Ovale in Children Over One Year of Age
Group No. Infants No. CCM %
HIV-infected 90 9 10.0
HIV-uninfected 449 34 7.6
HIV-indeterminate 19 3 15.8
All infants 558 46* 8.2
PDA and ASD in infants ,2 months of age, right-sided lesions that did not
persist, and PFOs in children less than 1 year were excluded. *Three infants had
a PFO plus an additional lesion resulting in 49 lesions among 46 infants.
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years of life has been well documented in a large percentage of
patients. In contrast, spontaneous closure of a patent ductus
arteriosus after 3 months of age is rare (20,21). To date, there
are no studies describing the course of a trivial patent ductus
arteriosus using serial echocardiography.
Effect of vertically transmitted HIV-infection. In contrast
to earlier limited reports (5,6), the prevalence of congenital
cardiovascular malformations was not significantly different
between HIV-infected (8.9%) and HIV-uninfected (5.6%)
children. With sample sizes available, this study had over 80%
statistical power to detect differences in the prevalence of
congenital cardiovascular malformations of 6% in HIV-
uninfected children versus 16% in HIV-infected children (sig-
nificance level 5 0.05, one-sided). The power of the study to
detect statistically significant differences was somewhat dimin-
ished because of a lower than originally anticipated vertical
transmission rate of 16.7% for the Neonatal Cohort.
It is likely that HIV-1 infection in a substantial percentage
of vertically transmitted cases occurs after the completion of
cardiac development at 6 to 8 weeks of fetal age (8 to 10 weeks’
gestational age). Studies on children indicate that a majority of
vertically transmitted cases occurs either late in pregnancy or
during the perinatal period (22,23).
The HIV-infection status of the child did not correlate with
maternal lymphocyte subsets (CD4 cell count and percent).
More detailed analyses of immunologic characteristics associ-
ated with mother–infant HIV-1 transmission are provided
elsewhere (24). Recent advances in the understanding of
vertical HIV-1 infection have yielded additional tools for the
study of the mother, fetus and infant exposed to HIV-1 that
were not available at the onset of the P2C2 HIV Study.
Subclinical cardiovascular malformations and patent fora-
men ovale. Because of their potential long-term clinical im-
pact, subclinical lesions, defined as uniformly silent lesions,
were included in the P2C2 analyses of congenital cardiovascu-
lar malformation prevalence. The subclinical lesions seen in
the Neonatal Cohort were bicuspid aortic valve without steno-
sis or regurgitation, persistent left superior vena cava and
coronary arteriovenous fistula. These subclinical lesions ac-
counted for 6 of the 36 lesions diagnosed (16.7%) and 5 of the
18 lesions that persisted at 1 year of age (27.8%) in the
Neonatal Cohort.
The fate of a small coronary arteriovenous fistula diagnosed
in childhood is not established. The incidence of small coro-
nary arteriovenous fistulae is not insignificant in adult popula-
tions (0.02% to 2.1%) (25–27), with an incidence of 0.18%
reported in the largest series (25). Small coronary arterio-
venous fistulae, such as the three identified in our Neonatal
Cohort, are usually clinically silent with no accompanying
murmurs or symptoms (28,29).
Diagnosis of a patent foramen ovale on a screening echo-
cardiogram is of potential clinical importance because of its
possible association with cerebral and peripheral embolic
events (30). Because of its high prevalence in normal patients,
however, the diagnosis of a patent foramen ovale was not
included in the primary analyses of congenital cardiovascular
malformation prevalence in the P2C2 study.
Study limitations. The study examined only the rates of
congenital cardiovascular malformations in live-born children
and did not address the rate and potential causes of fetal loss
secondary to HIV-1 infection. Potentially, there may have been
additional cases of congenital cardiovascular malformations
that were not included in the study due to fetal demise.
Conventional clinical diagnostic criteria were utilized for
the diagnosis of structural lesions. By several quality control
measures, there was good agreement on the diagnosis of major
and minor congenital cardiovascular malformations. The lack
of uniform criteria for the diagnosis of congenital cardiovas-
cular malformations could not be corrected retrospectively
because imaging studies were not directed at the identification
or exclusion of all minor structural lesions. Based on the
quality control assessment, it is reasonably anticipated that any
bias inherent in the study owing to diagnostic criteria would
have been evenly divided between HIV-infected and HIV-
uninfected children. The unique feature of this report relates
to the comprehensive echocardiographic evaluation and
follow-up of large cohorts of HIV-infected and HIV-
uninfected children of HIV-infected women.
Conclusions. In a prospective study of children born to
HIV-infected women, there was no statistically significant
difference in the prevalence of congenital cardiovascular mal-
formations in HIV-infected versus HIV-uninfected children.
Rates of congenital cardiovascular malformations in both the
HIV-infected and HIV-uninfected children, as determined by
early screening echocardiography, were five- to ten-fold higher
than rates reported in population-based epidemiologic studies
but not higher than in normal populations similarly screened.
The use of echocardiography as the method of case detection
and the timing of screening were important in comparisons of
congenital cardiovascular malformation prevalence. Poten-
tially important subclinical congenital cardiovascular malfor-
mations were detected by screening echocardiography, but
both their natural history and impact on the clinical course of
children exposed to maternal HIV-1 infection are unknown.
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